Back

Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study

21 May 2022 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pharmacology in heart failure - what is in horizon? Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2022

About the speaker

Photo
Mr Johan Larsson

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
Professor G. Filippatos (Athens, GR)
Abstract Slides
Presentation thumbnail
Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy
Doctor P. Garcia-Pavia (Majadahonda, ES)
Abstract Slides
Presentation thumbnail
Intravenous infusion of the beta-3 adrenergic receptor antagonist APD418 improves left ventricular function in dogs with systolic heart failure despite long-term therapy with beta-blockers
Professor H. Sabbah (Detroit, US)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology in heart failure - what is in horizon?

The Event

Event poster

Heart Failure 2022

21 May - 24 May 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources